Silver Book Fact

Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.

Neer, Robert M., et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM. 2001; 344(19): 1434-41. http://content.nejm.org/cgi/content/abstract/344/19/1434

Reference

Title
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Publication
NEJM
Publication Date
2001
Authors
Neer, Robert M., et al.
Volume & Issue
Volume 344, Issue 19
Pages
1434-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • 30 drugs are currently in development for osteoporosis.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…